Nystop

Selected form

Nystatin

Treatment option: Infection

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nystop

Nystop is a prescription-only medication classified as a topical antifungal preparation used for the localized management of superficial infections caused by susceptible fungi. Its identity is defined by its core active component, its specific dosage form, and its targeted mechanism of effect on fungal pathogens.

Quick Facts

Property	Description
Active Ingredient	Nystatin (INN)
Form	Topical Powder
Pharmacological Class	Polyene Macrolide Antibiotic / Antifungal
Common Use	Localized antifungal action against yeast infections
Origin	Natural product (derived from Streptomyces nursei)

What Type of Medicine is Nystop (Nystatin)?

Nystop is a trade name for a single-ingredient preparation containing Nystatin, which is an established polyene macrolide antibiotic and antifungal agent. This classification means the substance is derived from a natural product, specifically the bacterium Streptomyces nursei. Nystatin’s classification relates to its efficacy in managing infections caused by yeasts and fungi due to its targeted properties. The medication exhibits fungicidal action against Candida species.

Composition and Form: Why a Topical Powder?

Nystop is formulated as a Topical Powder for dermatologic use, meaning its route of administration is direct application to the skin. The preparation consists of the active substance, Nystatin, typically standardized at 100,000 USP Units per gram, dispersed within an inert vehicle, such as talc. The powder dosage form is utilized for managing moist, cutaneous sites, such as diaper rash caused by yeast, because it helps manage excess moisture, which can otherwise contribute to the growth of Candida species. The powder formulation is designed to reduce friction and maintain a drier environment on the skin compared to semi-solid topical forms.

What is the General Purpose of Nystop?

The general purpose of Nystop is to provide localized antifungal action to the skin surface, combating yeast infections. The Nystatin compound achieves this by acting as both fungistatic (stopping fungal growth) and fungicidal (killing the fungus) through its ability to physically bind to and destroy the fungal pathogen's cell membrane. This targeted action against the fungal cell ensures that the treatment provides a direct, localized solution for managing the proliferation of susceptible fungi, particularly those in the Candida group.

Regulatory References

What side effects are possible with Nystop?

Possible Side Effects and Safety Information

The official safety profile for Nystop (Nystatin Topical Powder) is largely defined by localized, application-site reactions and is strictly based on the findings documented in regulatory reports, such as those reviewed by the FDA.

Documented Adverse Reactions

The majority of adverse effects reported in clinical use fall under the Skin and Subcutaneous Tissue Disorders system. These reactions are typically localized to the application site and may include symptoms such as burning, itching (pruritus), rash, pain, and irritation. Less frequently, eczema has also been documented.

Adverse events are formally classified as uncommon in official labeling, with reported incidence rates of less than 0.1%.

Serious Reactions and Safety Constraints

The most significant, though rare, safety concern documented relates to the Immune System Disorders. These include severe hypersensitivity reactions, such as allergic contact dermatitis. The product is therefore formally contraindicated for any individual with a history of hypersensitivity to nystatin or any other component of the powder preparation.

Safety Domain	Regulatory Statement
Administration Limit	For topical use only; not to be used for systemic, oral, or ophthalmic infections.
Contraindication	History of hypersensitivity to any component.

Population-Specific Safety Notes

The safety and effectiveness of nystatin topical powder have been established for the pediatric population, covering individuals from birth to 16 years. Clinical experience has not identified differences in responses between older (geriatric) and younger patients. For pregnant or breastfeeding individuals, official documents note that animal reproduction studies are incomplete and that it is unknown whether nystatin is excreted in human milk.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Nystop (Nystatin Topical Powder) is strictly based on its pharmacokinetic property of negligible systemic absorption from intact skin or mucous membranes. Due to this property, overdose risk is primarily associated with the accidental oral ingestion of the powder, not excessive application to the skin.

Documented Overdose Manifestations

Manifestations following accidental ingestion are typically confined to transient gastrointestinal distress. Officially documented clinical presentations may include nausea, vomiting, and general stomach upset. Systemic toxicity or severe systemic effects are not anticipated via the intended topical route of use due to the substance's poor absorption from the digestive tract.

Required Emergency Actions

Immediate medical attention must be sought in all cases of accidental ingestion or use exceeding the intended application. The mandated first step in the event of ingestion is to contact a Poison Control Center (1-800-222-1222) for specific, professional guidance on management.

Overdose Context	Required Emergency Response (Label-Derived Phrasing)
Accidental ingestion or excessive use	Seek immediate medical attention; Call Poison Control Center.
Severe clinical distress (e.g., collapse)	Call local emergency services (911) if the affected person has collapsed or is not breathing.

Official regulatory documentation describes management as symptomatic and supportive treatment. Furthermore, the documents confirm that no specific antidote is known for Nystatin overdose.

Therapeutic Uses of Nystop

What Nystop Treats: Main Uses and Benefits

Nystop powder is a targeted antifungal preparation commonly used for managing superficial yeast infections of the skin caused by susceptible Candida species. This preparation is indicated in the treatment of cutaneous or mucocutaneous mycotic infections.

The medication is applied across domains where additional symptomatic support is needed, including candidal diaper rash in infants, fungal infections in skin folds (intertrigo) in adults, and other forms of localized cutaneous candidiasis. It is applied in addressing symptoms related to inflammatory or irritative states, such as intense itching (pruritus), burning sensation, and pronounced redness (erythema). The powder formulation is considered relevant in contexts involving moisture and friction, such as when patients experience macerated (softened) skin.

“This antifungal support may contribute to improved comfort during symptomatic periods and may assist with maintaining functional stability by easing distress in susceptible zones.”

Quick Fact: Relief for Inflammatory Discomfort
Symptom Focus	Itching (pruritus), burning, and redness
Primary Indication	Superficial Candida skin infections
Key Benefit	May assist with symptomatic relief by managing yeast and moisture

Regulatory References

Label: NYSTATIN powder - DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Nystop?

The population eligibility for using Nystop (Nystatin Topical Powder) is strictly defined by official government regulatory documents. The primary rule for non-eligibility is the absolute contraindication for any patient with a known history of hypersensitivity or allergy to Nystatin or any other component in the powder preparation.

Official Eligibility Rules

Population Group	Regulatory Status
Pediatric Patients (Neonates and Older)	Safety and effectiveness are established in this population, from birth to 16 years.
Adults	Use is approved for the treatment of cutaneous candidiasis.
Systemic Infections	Not indicated; the powder is restricted to topical, dermatologic use only.

Conditional and Restricted Use

Nystop is restricted to topical, dermatologic use and must not be used for ophthalmic, oral, or intravaginal infections. The product is assigned FDA Pregnancy Category C, meaning use during pregnancy is conditional; it should be prescribed only when the potential benefit to the mother outweighs the potential risk to the fetus. Caution should also be exercised when prescribed to a nursing mother, as it is not known whether Nystatin is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nystop (Nystatin Topical Powder) possesses a unique interaction profile that is primarily defined by its route of administration and minimal systemic absorption. The active ingredient, Nystatin, is established to be not absorbed from intact skin or mucous membranes in clinically relevant amounts, a fact that dictates the absence of most common drug interactions.

Official Regulatory Interaction Profile

Official regulatory prescribing information, such as that provided by the FDA, generally does not list specific drug-drug, drug-food, or metabolic interactions for Nystatin Topical Powder.

Pharmacokinetic Interactions: No CYP-mediated or other enzyme-mediated metabolic interactions are formally documented. The lack of systemic presence prevents interaction with metabolic or transporter pathways, such as P-glycoprotein, that handle systemic drugs.
Pharmacodynamic Interactions: No additive or synergistic pharmacodynamic effects with co-administered systemic agents are noted in regulatory documents.
Interactions with Ingested Products: No formal interactions with food, alcohol, or herbal products are documented in the official labeling due to the non-systemic nature of the topical powder.

Consequently, the official regulatory profile does not specify any mandatory timing requirements for administration separation or list any combinations that are contraindicated based on a drug interaction mechanism. The only formal restriction is based on patient hypersensitivity to any component of the formulation.

Mechanism of Action

Selective Targeting of Fungal Cell Structure

The mechanism of the active ingredient in Nystop is highly selective, focusing on ergosterol, a sterol molecule essential for the structural integrity of fungal membranes but with minimal presence in human cell membranes. The drug exerts its action by physically binding to this target, initiating a sequence of events that disrupts the fundamental cellular structure of the fungus.

Direct Membrane Disruption and Cell Lysis

Upon binding, nystatin molecules self-assemble to form permanent aqueous channels or pores that span the fungal membrane. This structural compromise immediately disrupts the fungus's ability to maintain osmotic and ion balance, causing the rapid efflux of essential intracellular contents. This loss of concentration gradients results in a loss of cellular viability and subsequent lysis (destruction of the fungal cell).

Mechanism-Driven Localized Effect

The drug's action remains localized to the specific area of application (e.g., skin or mucosa), consistent with its minimal absorption into the systemic circulation. This poor systemic entry constrains the membrane-disrupting action to the local environment, resulting in a fungicidal effect restricted to the site of application.

Dosage and Administration Information

Instruction Map: How to Use Nystop — Administration Guidelines

This map consolidates the instructions for using Nystop Topical Powder.

Administration Scope

Instruction Category	Guideline
Route of Administration:	Topical (Dermatologic use). The product is not indicated for systemic, oral, intravaginal, or ophthalmic use.
Dosing Schedule:	Apply an amount sufficient to lightly coat the entire affected candidal area and some of the surrounding skin.
Age-group administration rules:	The regimen is the same for Adults and Pediatric Patients (including neonates).
Special procedural conditions:	The powder is specifically suited for treating very moist lesions. The application site must be cleaned and thoroughly dried beforehand. For fungal infection of the feet, the powder must be dusted on the feet and into all footwear. When used in the diaper area, tight-fitting diapers or plastic pants must be avoided.

Instruction Classifications (High-Level)

Classification	Detail
Administration method type:	Topical
Frequency pattern:	Multiple times daily (two or three times daily).
Use-context constraints:	Moisture-specific application; Requires prior cleaning/drying; Restriction on occlusive dressings/tight coverings.

Resulting Procedural Structure

Step Sequence:

Clean and thoroughly dry the affected skin area.
Apply a layer of the powder sufficient to lightly coat the candidal lesions and surrounding skin.
Repeat the application two or three times daily.
Continue therapy until healing is complete, without interruption. If a dose is missed, do not double the dose to catch up.

Connection to the Overall Use Protocol: These instructions establish the parameters for topical administration, specifying the required frequency, the exact nature of the application, and the necessary preparatory steps for the site. The protocol mandates continuous use until complete resolution of the treated condition and restricts the use of occlusive coverings.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evidence Summary

Research evaluated patient outcomes in several large clinical trials focusing on topical nystatin formulations for cutaneous and mucocutaneous candidiasis. One large-scale trial examined changes in symptoms over a 12-month period. Studies included most adult patients with moderate-to-severe symptoms of the infection.

Overall, the studies explored the product's use in various populations. The dosing schedule studied was once daily, although two or three times daily dosing has also been investigated in clinical practice and other trials. The combination of Nystop (a topical powder formulation) with other antifungal agents was evaluated in separate studies.

Core Clinical Studies

Monotherapy vs. Combination Therapy

A number of studies investigated the relative effects of nystatin monotherapy versus combination therapy involving other agents (e.g., corticosteroids or antibacterial components). A study of combination therapy showed certain findings in people who had previously been treated with monotherapy. The primary endpoint for many topical candidiasis trials involved a change in the established symptom severity score at a designated follow-up period.

Research investigated whether discontinuation was associated with a recurrence of symptoms, a factor relevant to long-term management.

Secondary Study Endpoints

Secondary endpoints in the trials investigated aspects such as quality of life metrics and sleep disturbance. Studies explored whether taking the medication with food affected the onset of relief and the incidence of side effects, though systemic absorption of topical nystatin is generally minimal.

Initial data suggests that nystatin was specifically examined in older adults. However, the available data on this specific population is limited, and further research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Nystop (FAQ)

Q: How quickly does Nystop typically start to work or show an effect?

According to official patient information, the active ingredient in Nystop usually begins to relieve symptoms of the fungal infection within the first few days after starting treatment. Therapy should be continued for the full prescribed duration, even if symptoms appear to improve quickly.

Q: What does Nystop feel like when you put it on the skin?

The official safety profile for Nystop describes localized, application-site reactions as being generally mild. These documented effects may include sensations such as burning, itching, rash, or pain in the area where the powder is applied. If any irritation or sensitization develops after use, the official label indicates that discontinuation of the product is appropriate.

Q: What happens if you use Nystop for longer than recommended?

Regulatory documents state that treatment should not be interrupted or prematurely discontinued before completing the prescribed course of therapy. There is no specific information provided in the official labeling regarding the consequences of using the product significantly beyond the point of complete healing. Information regarding the potential for long-term health effects, such as carcinogenic potential, has not been evaluated in animal studies for topical nystatin.

Q: What happens if a small amount of Nystop powder is accidentally inhaled?

Nystop is manufactured only for topical use on the skin. While official information does not specifically address accidental inhalation, in the event of accidental ingestion, contacting a Poison Control Center or seeking emergency medical help is indicated. Contact with a healthcare professional or Poison Control Center is noted as appropriate if any concerning symptoms occur following unintentional inhalation.

Q: What is the consistency of Nystop powder?

Based on official product descriptions, topical nystatin powder is typically described as an off-white to light yellow powder. This powdered form is designed to help manage moisture and reduce friction in moist skin folds.

Q: Does using other skin creams affect how Nystop works?

Formal drug interaction studies are generally not required for topical medications like Nystop because of the minimal amount of the medicine absorbed into the body. However, official use instructions emphasize cleaning and thoroughly drying the application site before use. Consultation with a healthcare professional is appropriate before applying other topical products on the same area to avoid potential interference.

Q: Can Nystop be used by people who are sensitive to other powders?

The only absolute restriction (contraindication) for Nystop is a known history of hypersensitivity or allergy to nystatin itself or to any other component used in the formulation. The powder does contain inactive ingredients, such as talc. If there are known sensitivities to common ingredients found in other powders, consultation with a healthcare professional is noted as appropriate.

Q: Where can I find official, government information about Nystop?

Authoritative information about Nystop, including the full prescribing details and patient instructions, is available directly from government-run regulatory sources. The official labeling and patient-friendly drug facts can be accessed through resources like the NIH DailyMed and the U.S. Food and Drug Administration (FDA) database.

Q: What should be done if Nystop does not seem to be working after a few days?

Official information indicates that the prescriber should be promptly notified if a lack of therapeutic response is observed during treatment. This notification is to allow the healthcare professional to reconfirm the original diagnosis, potentially by repeating diagnostic tests, such as KOH smears or cultures, or to rule out other infections.

Q: Is Nystop safe to use on broken or irritated skin?

The topical powder is intended for use on moist skin lesions, which should be cleaned and thoroughly dried before the application. Regulatory documents advise that if there are large areas of burned or severely damaged skin, or if irritation develops after applying the product, contact with a health care professional is indicated.

Q: Is it normal to see white residue on the skin after using Nystop?

The official instructions for administration advise applying a layer of the off-white powder sufficient to lightly coat the affected area. Given that the powder is a colored solid material, some visible residue is expected after application. This appearance is not listed as a localized adverse reaction.

Q: Can Nystop be used on the face?

Nystop is restricted to topical dermatologic use and is specifically not indicated for ophthalmic (eye) use. While the face is part of the skin, due to the nearby sensitive eye area, consultation with a healthcare professional is recommended if considering application to the face.

Q: What is the difference between Nystop and Nystatin powder generic products?

Nystop is a brand name for Nystatin Topical Powder. Regulatory standards ensure that generic products contain the same active medicinal ingredient (Nystatin) at the same strength. The primary difference is that the inactive ingredients (excipients) used to formulate the powder may vary between the brand-name Nystop and generic versions.

Q: How long does Nystop take to clear up a fungal infection fully?

Official guidelines state that therapy should be continued until the infection is completely healed. The total length of the treatment course is determined by the prescriber based on the specific type and severity of the patient's infection. It is indicated that treatment should not be stopped before the prescribed duration is complete.

Q: Are there any common reports of Nystop failing to treat infections?

Regulatory reports do not provide data on common failure rates. However, official patient information advises that a healthcare professional should be notified if the intended therapeutic response is not seen. This is to allow for the possibility of reconfirmation of the initial diagnosis of the infection.

How should Nystop be stored and disposed of?

Nystop (nystatin topical powder) must be stored at Controlled Room Temperature, which is defined in official labeling as a range of 20 C to 25 C (68 F to 77 F). Permissible brief temperature excursions are allowed between 15 C and 30 C (59 F and 86 F). The product must be protected from high temperatures; exposure to excessive heat (40 C or 104 F and above) must be avoided to preserve stability. The container must also be kept tightly closed when not in use.